Daniele Massera is a Cardiology physician affiliated with NYU Langone Health. OpenAlex indexes 119 publications with 1,478 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
530 1st Ave # 9n
New York, NY 10016
Telephone
646-501-0119Provider last certified this registry record 12 May 2026.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202521 payments$48,577openpaymentsdata.cms.gov ↗
- Chiesi USA, Inc.Program year20257 payments$11,138openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
90.6%Beta blocker30.3%Metoprolol Succinate78%Bisoprolol Fumarate22%Part D≥72 patientsCardiac Myosin Inhibitor16.2%Camzyos100%Part D≥17 patients+ 8 more classes in this area
Blood & clotting
5.3%Factor Xa inhibitor5.3%Eliquis100%Part D≥15 patientsMetabolism & gastrointestinal
4.1%SGLT2 inhibitor4.1%Jardiance100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years
Journal of the American Heart Association
2025 - Plasma Proteomic Assessment of Calcific Aortic Valve Disease in Older Adults
Journal of the American Heart Association
2025 - Medical, Surgical, and Interventional Management of Hypertrophic Cardiomyopathy
Circulation Cardiovascular Interventions
2025 - Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology
2024 - Mitral Leaflet Shortening as an Ancillary Procedure in Obstructive Hypertrophic Cardiomyopathy
The Annals of Thoracic Surgery
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Harvey Pass, MD
NYU Langone Health
Gareth Morgan, MD
NYU Langone Health
Douglas Kondziolka, MD
NYU Langone Health
Nathan Levin, MD
NYU Langone Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”